KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Research & Development (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Research & Development for 16 consecutive years, with $10.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 20.37% to $10.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.2 million through Dec 2025, down 28.32% year-over-year, with the annual reading at $54.2 million for FY2025, 28.32% down from the prior year.
  • Research & Development hit $10.3 million in Q4 2025 for Inovio Pharmaceuticals, down from $13.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $92.3 million in Q4 2021 to a low of $10.3 million in Q4 2025.
  • Historically, Research & Development has averaged $32.7 million across 5 years, with a median of $23.4 million in 2023.
  • Biggest five-year swings in Research & Development: surged 250.91% in 2021 and later crashed 59.04% in 2023.
  • Year by year, Research & Development stood at $92.3 million in 2021, then plummeted by 54.37% to $42.1 million in 2022, then plummeted by 59.04% to $17.3 million in 2023, then dropped by 25.31% to $12.9 million in 2024, then fell by 20.37% to $10.3 million in 2025.
  • Business Quant data shows Research & Development for INO at $10.3 million in Q4 2025, $13.3 million in Q3 2025, and $14.5 million in Q2 2025.